Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN NIVEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1336167634
CMS profile
60481
Location
MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$5.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $5.92 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $5.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN NIVEN

NPI 1336167634 · CMS profile ID 60481

Allopathic & Osteopathic Physicians / Dermatology

MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $5.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $5.9210/22/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743814049 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30.02 2
PY2020 $5.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $547,115.16 88
PY2024 Principal investigator $919,823.31 487
PY2023 Recipient $1,200.00 1
PY2023 Principal investigator $635,503.38 419
PY2022 Principal investigator $475,737.00 87
PY2021 Principal investigator $161,162.86 33
PY2020 Principal investigator $161,071.72 49
PY2019 Principal investigator $202,395.85 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

487 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,058.80 12/31/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
M23-716 Rinvoq Ph 3 Alopecia Areata No dispute reported 06/30/2026 1100766533
Principal investigator 1 ABBVIE INC. $7,690.00 12/30/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100763324
Principal investigator 1 ABBVIE INC. $14,698.00 12/30/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100763326
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,327.84 12/18/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793042
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36,891.58 12/11/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500482
Principal investigator 1 ABBVIE INC. $2,057.50 12/05/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100759459
Principal investigator 1 ABBVIE INC. $18,497.68 12/05/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100759461
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,166.74 12/02/2024 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031490
Principal investigator 1 Arcutis Biotherapeutics, Inc. $7,000.00 12/02/2024 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031492
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,423.88 12/02/2024 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031732
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,125.00 12/02/2024 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031734
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,566.92 12/02/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500022
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,991.76 11/13/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793040
Principal investigator 1 ABBVIE INC. $11,265.00 11/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100753523
Principal investigator 1 ABBVIE INC. $5,786.00 11/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata No dispute reported 06/30/2026 1100753525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 11/01/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125498947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $66,192.18 11/01/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125499035
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $170.00 10/31/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793038
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $85.00 10/17/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793036
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,327.84 10/15/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793034
Principal investigator 1 ABBVIE INC. $21,715.00 10/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100745966
Principal investigator 1 ABBVIE INC. $4,988.00 10/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100746002
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $255.00 09/30/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793032
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,215.75 09/24/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793030
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $73,083.90 09/11/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125497295
Principal investigator 1 ABBVIE INC. $24,570.00 09/04/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100740246
Principal investigator 1 ABBVIE INC. $9,178.00 09/04/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100740266
Principal investigator 1 ABBVIE INC. $12,035.00 09/04/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1100740268
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901078
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901082
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901087
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901091
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901100
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901104
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901108
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901113
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901117
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901121
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901126
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901130
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901134
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901138
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901147
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901151
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901155
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901160
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901165
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901169
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901173
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901177
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901181
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901186
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901194
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901198
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901202
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901206
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901210
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901215
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901219
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901223
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901228
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901232
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901240
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901244
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901249
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901253
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901257
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901262
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901266
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901270
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901274
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901278
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901287
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901291
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901296
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901300
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901304
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901308
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901313
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901317
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901321
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901326
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901334
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901338
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901342
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901346
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901351
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901355
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901359
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901364
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901368
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901372
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901380
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901385
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901389
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901393
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901398
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901402
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901406
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901410
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901415
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901419
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901427
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901431
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901435
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901440
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901444
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901448
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901453
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901457
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901461
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901465
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901474
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901478
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901482
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901486
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901491
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901495
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901499
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901503
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901508
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901512
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901525
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901529
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901533
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901537
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901542
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901546
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901550
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901554
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901558
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901563
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901572
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901576
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901580
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904702
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904706
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904710
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904714
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904719
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904723
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904727
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904736
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904740
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904744
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904749
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904753
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904757
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904761
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904765
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904770
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904774
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904783
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904787
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904791
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904795
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904799
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904803
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904807
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904812
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904816
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904820
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904829
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904833
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904837
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904842
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904846
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904850
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904855
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904859
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904863
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904868
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904876
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904881
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904885
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904889
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904894
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904898
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904902
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904906
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904910
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904914
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926537
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926541
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926546
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926550
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926558
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926562
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926566
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926571
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926575
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926579
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926583
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926588
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926592
Principal investigator 1 Dermavant Sciences, Inc. $46.31 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926596
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926605
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926609
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926614
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926618
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926622
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926626
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926631
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926635
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926639
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926644
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926652
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926656
Principal investigator 1 Dermavant Sciences, Inc. $207.75 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926661
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926665
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926669
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926674
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926678
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926682
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926687
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926691
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926699
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926703
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926708
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926712
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926717
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926721
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926726
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926731
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926735
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926739
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926748
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926752
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926756
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926760
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926764
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926768
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926772
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926776
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926781
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926785
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926794
Principal investigator 1 Dermavant Sciences, Inc. $218.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926798
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926803
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926807
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926811
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926815
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926819
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926824
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926828
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926832
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926841
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926845
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926849
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926854
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926858
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926862
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926866
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926870
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926874
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926878
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926887
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926891
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926896
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926900
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926904
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926908
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926912
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926917
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926921
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926925
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926933
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926938
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926942
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926946
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926950
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926954
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926959
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926963
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926967
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926971
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926984
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926988
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926993
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926997
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927001
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927005
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927010
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927014
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927018
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927023
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927032
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927036
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927040
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930166
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930170
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930174
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930179
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930183
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930187
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930191
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930200
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930204
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930208
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930212
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930216
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930220
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930224
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930228
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930233
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930237
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930245
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930249
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930253
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930258
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930262
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930266
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930270
Principal investigator 1 Dermavant Sciences, Inc. $257.48 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930274
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930278
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930283
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930291
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930295
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930299
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930303
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930307
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930311
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930315
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930320
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930324
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930328
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930336
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930340
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930344
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930349
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930353
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930357
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930361
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930365
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930369
Principal investigator 1 Dermavant Sciences, Inc. $214.77 08/03/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127930373
Principal investigator 1 ABBVIE INC. $10,606.14 08/02/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100734276
Principal investigator 1 Dermavant Sciences, Inc. $50.00 07/31/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127881846
Principal investigator 1 Dermavant Sciences, Inc. $50.00 07/31/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127881850
Principal investigator 1 Dermavant Sciences, Inc. $50.00 07/31/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127881854
Principal investigator 1 Dermavant Sciences, Inc. $50.00 07/31/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127881858
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $62,953.29 07/24/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125494363
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879786
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879790
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879795
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879799
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879803
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879808
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879812
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879816
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879820
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879824
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879828
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879833
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879837
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879841
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879845
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879849
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879853
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879858
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879862
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879866
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879870
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879875
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879879
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879883
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879887
Principal investigator 1 Dermavant Sciences, Inc. $97.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879891
Principal investigator 1 Dermavant Sciences, Inc. $50.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879895
Principal investigator 1 Dermavant Sciences, Inc. $50.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879900
Principal investigator 1 Dermavant Sciences, Inc. $50.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879904
Principal investigator 1 Dermavant Sciences, Inc. $120.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879908
Principal investigator 1 Dermavant Sciences, Inc. $120.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879913
Principal investigator 1 Dermavant Sciences, Inc. $120.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879917
Principal investigator 1 Dermavant Sciences, Inc. $120.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879921
Principal investigator 1 Dermavant Sciences, Inc. $120.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879925
Principal investigator 1 Dermavant Sciences, Inc. $120.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879930
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879934
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879938
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879942
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879947
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879951
Principal investigator 1 Dermavant Sciences, Inc. $1,072.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879955
Principal investigator 1 Dermavant Sciences, Inc. $1,072.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879959
Principal investigator 1 Dermavant Sciences, Inc. $1,072.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879964
Principal investigator 1 Dermavant Sciences, Inc. $1,072.50 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879968
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879972
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879976
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879980
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879984
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879988
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879996
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880000
Principal investigator 1 Dermavant Sciences, Inc. $100.00 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880004
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880009
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880013
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880017
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880021
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880025
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880029
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880033
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880037
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880041
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880045
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880050
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880054
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880058
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880062
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880067
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880071
Principal investigator 1 Dermavant Sciences, Inc. $257.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880075
Principal investigator 1 Dermavant Sciences, Inc. $218.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880079
Principal investigator 1 Dermavant Sciences, Inc. $218.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880083
Principal investigator 1 Dermavant Sciences, Inc. $218.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880087
Principal investigator 1 Dermavant Sciences, Inc. $218.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880091
Principal investigator 1 Dermavant Sciences, Inc. $218.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880096
Principal investigator 1 Dermavant Sciences, Inc. $218.48 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880100
Principal investigator 1 Dermavant Sciences, Inc. $214.77 07/23/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127880105
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,459.00 07/23/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793018
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $567.00 07/23/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793020
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $85.00 07/23/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793022
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $255.00 07/23/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793024
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $992.00 07/23/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793026
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,991.76 07/23/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793028
Principal investigator 1 Galderma Laboratories, L.P. $132.10 07/18/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab No dispute reported 06/30/2026 1156049045
Principal investigator 1 ABBVIE INC. $1,652.82 07/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 1100730142
Principal investigator 1 ABBVIE INC. $1,500.00 07/16/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 1100730062
Principal investigator 1 ABBVIE INC. $20,191.82 07/05/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100727394
Principal investigator 1 ABBVIE INC. $12,035.00 07/05/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100727426
Principal investigator 1 ABBVIE INC. $15,735.82 06/06/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100722516
Principal investigator 1 ABBVIE INC. $12,035.00 06/06/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (Sleep Up) No dispute reported 06/30/2026 1100722518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $35,927.30 05/22/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125491564
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,543.59 05/17/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793016
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,338.89 05/13/2024 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031488
Principal investigator 1 ABBVIE INC. $6,388.84 05/09/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100718206
Principal investigator 1 Arcutis Biotherapeutics, Inc. $266.00 05/06/2024 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031730
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,663.92 04/17/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793014
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $68,783.66 04/17/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125489803
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,606.95 04/15/2024 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031486
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $170.00 04/10/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793006
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $170.00 04/10/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793008
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $255.00 04/10/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793010
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $851.00 04/10/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793012
Principal investigator 1 Arcutis Biotherapeutics, Inc. $220.00 04/08/2024 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031728
Principal investigator 1 ABBVIE INC. $6,987.84 04/05/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100713284
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,530.43 04/02/2024 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031484
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,449.07 03/18/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793004
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 03/15/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876520
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 03/15/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,959.30 03/15/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125488153
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 03/09/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876381
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 03/09/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876385
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 03/09/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876389
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 03/09/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876393
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 03/09/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876397
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876343
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876347
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876352
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876356
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876360
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876364
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876368
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876372
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 03/07/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,755.00 03/06/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125487485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 03/06/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125487487
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,879.67 02/16/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793002
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,176.52 02/14/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486295
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $340.00 02/12/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792998
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $255.00 02/12/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793000
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $39,796.96 02/09/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486127
Principal investigator 1 Arcutis Biotherapeutics, Inc. $209.95 02/05/2024 Non-covered Recipient Entity
Lenus Research & MedicalGroup, LLC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031482
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36,299.07 02/02/2024 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125484819
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,785.15 01/25/2024 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151792996
Principal investigator 1 ABBVIE INC. $1,500.00 01/18/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 1100700515
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875360
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875364
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875369
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875373
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875377
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875381
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875385
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875390
Principal investigator 1 Dermavant Sciences, Inc. $1,238.02 01/17/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875394
Principal investigator 1 ABBVIE INC. $1,652.82 01/11/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 1100699899
Principal investigator 1 ABBVIE INC. $11,000.00 01/10/2024 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100699307
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,237.51 01/03/2024 Non-covered Recipient Entity
SKIN SEARCH OF ROCHESTER INC
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031726